Home > Maligne hematologie > Lymfoïde ziekten > Non-Hodgkin lymfomen (NHL) > Diffuus grootcellig B-cel NHL > Hovon 136

Hovon 136

Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 29-5-2024, 0:30